MARION's CARDIZEM SR COULD REPLACE ABOUT 50% OF CURRENT DILTIAZEM VOLUME WITHIN TWO YEARS OF APPROVAL: 120-DAY EXTENDED TERMS PLANNED FOR LAUNCH